title: Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
abstract: BACKGROUND
  The cumulative exposition to biologics is increasing with prolonged treatment with a certain biologic or consecutive biological treatment. However, long-term safety data are limited available.
  
  
  OBJECTIVE
  The aim of this study was to prospectively evaluate the 5-year safety of biological treatment for psoriasis in daily practice.
  
  
  METHODS
  A cohort of 173 psoriasis patients on biologics was prospectively followed for 5 years. All adverse events reported were documented and analysed. Primary endpoint was the percentage of patients reporting at least one serious adverse event. The rate of malignancies, serious infections and serious cardiovascular events was compared with the general population incidence rate. The nature and rate of dermatological adverse events was compared with a group of prospectively followed rheumatoid arthritis patients on TNF-α blocking therapy.
  
  
  RESULTS
  Between February 2005 and April 2010, 173 patients were enrolled in the registry and went through a total number of 263 treatment episodes. The total number of patient-years of follow-up in the registry was 409. The number of patient-years was the highest for etanercept. Forty-nine patients (28%) reported 88 serious adverse events. Only one serious adverse event was certainly causally related to the biologic and 21 events (24% of SAEs) were considered possibly related. The incidence of malignancies, serious infections and serious cardiovascular events was comparable with the population incidence rate, except for skin malignancies. The incidence of skin malignancies was significantly higher than the general population incidence rate. The nature and rate of dermatological adverse events differed from the rheumatoid arthritis cohort.
  
  
  CONCLUSIONS
  In this cohort, the safety of biological therapies for psoriasis was favourable with a low incidence of therapy-related serious adverse events.
authors: Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. P.vanLumig@derma.umcn.nl
authors: P P M
authors: PP
authors: van Lümig
authors: R J B
authors: RJ
authors: Driessen
authors: M A M
authors: MA
authors: Berends
authors: J B M
authors: JB
authors: Boezeman
authors: P C M
authors: PC
authors: van de Kerkhof
authors: E M G J
authors: EM
authors: de Jong
mesh_terms: D000368:Aged; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D015897:Comorbidity; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016012:Poisson Distribution; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D012042:Registries; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D015415:Biomarkers